Page last updated: 2024-09-04

docetaxel anhydrous and pr-104

docetaxel anhydrous has been researched along with pr-104 in 1 studies

Compound Research Comparison

Studies
(docetaxel anhydrous)
Trials
(docetaxel anhydrous)
Recent Studies (post-2010)
(docetaxel anhydrous)
Studies
(pr-104)
Trials
(pr-104)
Recent Studies (post-2010) (pr-104)
12,1103,2166,92020511

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR1

Trials

1 trial(s) available for docetaxel anhydrous and pr-104

ArticleYear
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
    BMC cancer, 2012, Oct-25, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids

2012